Immunitybio Inc Asset Resilience Ratio
Immunitybio Inc asset resilience ratio. Immunitybio Inc (IBRX) has an Asset Resilience Ratio of 38.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Immunitybio Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immunitybio Inc (2015–2024)
Asset resilience ratio of Immunitybio Inc from 2015 to 2024. This chart shows how Immunitybio Inc's Asset Resilience Ratio has changed over time. Read IBRX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immunitybio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Immunitybio Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $197.57 Million | 38.07% |
| Total Liquid Assets | $197.57 Million | 38.07% |
Asset Resilience Insights
- Very High Liquidity: Immunitybio Inc maintains exceptional liquid asset reserves at 38.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immunitybio Inc Industry Peers by Asset Resilience Ratio
Compare Immunitybio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Immunitybio Inc Asset Resilience Ratio by Year (2015–2024)
Immunitybio Inc asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Immunitybio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.67% | $6.38 Million | $382.93 Million | +1.47pp |
| 2023-12-31 | 0.20% | $1.01 Million | $504.45 Million | -0.50pp |
| 2022-12-31 | 0.70% | $2.54 Million | $362.36 Million | -28.30pp |
| 2021-12-31 | 29.01% | $136.01 Million | $468.91 Million | +1.39pp |
| 2020-12-31 | 27.62% | $61.15 Million | $221.38 Million | +2.37pp |
| 2019-12-31 | 25.25% | $36.14 Million | $143.12 Million | -6.25pp |
| 2018-12-31 | 31.51% | $57.33 Million | $181.95 Million | -10.13pp |
| 2017-12-31 | 41.64% | $104.28 Million | $250.44 Million | -18.47pp |
| 2016-12-31 | 60.11% | $190.84 Million | $317.50 Million | +27.86pp |
| 2015-12-31 | 32.25% | $118.31 Million | $366.85 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more